Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SloveniaBack to Slovenia

Clinical trials in Ljubljana – page 7

95 clinical trials in Ljubljana, Slovenia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SloveniaOur site in SloveniaKlinicnaPreskusanja.si(opens in a new tab)
Ljubljana at a glance
95
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

95 trials in Ljubljana

Open in trial search

Phenylketonuria

Not recruiting

Study Comparing Sepiapterin and Sapropterin for Treating Phenylketonuria in Patients Aged 2 Years and Older

Registered drugNo placebo
Countries:SloveniaSlovenia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:(S)-2-Amino-6-(2-Hydroxypropanoyl)-7,8-Dihydropteridin-4(3H)-One
  • Sponsor:PTC Therapeutics Inc.

Dementia Alzheimer's type

Not recruiting

Study on AVP-786 for Treating Agitation in Alzheimer's Dementia Patients

Investigational
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Quinidine Sulfate
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Acute myeloid leukaemia

Not recruiting

Study on Midostaurin and Chemotherapy for Children with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Registered drugNo placebo
Countries:SloveniaSlovenia
  • Participants:0–17 years
  • Substances:Cytarabine
  • Sponsor:Novartis Pharma AG

Study on the Effectiveness and Safety of Guselkumab and Golimumab for Patients with Moderate to Severe Crohn's Disease

Not recruiting
Investigational
Countries:SloveniaSlovenia
  • Participants:18–64 years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Colitis ulcerative

Not recruiting

Study on the Effects of Guselkumab and Golimumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:SloveniaSlovenia
  • Participants:18–64 years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Growth hormone deficiency

Not recruiting

Study on the Effects of Somapacitan and Somatropin in Children with Growth Hormone Deficiency

Registered drugNo placebo
Countries:SloveniaSlovenia
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S

Pulmonary embolism

Not recruiting

Study on Reduced Dose of Alteplase for Patients with Intermediate-High-Risk Acute Pulmonary Embolism

Registered drug
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Assistance Publique Hopitaux De Paris

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:SloveniaSlovenia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Atypical haemolytic uraemic syndrome

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Adults with Atypical Hemolytic Uremic Syndrome Not Previously Treated with Complement Inhibitors

InvestigationalNo placebo
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Non-small cell lung cancer

Not recruiting

Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

Registered drug
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Relapsing multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:SloveniaSlovenia
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Multiple sclerosis relapse

Not recruiting

Study on Ofatumumab for Patients with Relapsing Multiple Sclerosis Transitioning from Fumarate-Based Therapies or Fingolimod

Registered drugNo placebo
Countries:SloveniaSlovenia
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Other cities in Slovenia

The busiest research cities in the country

All 18 cities in Slovenia

Clinical research in Ljubljana

What the registry says about research in the country

01 Autoimmune Conditions

Innovative research focusing on Sjögren's Syndrome and inflammatory bowel conditions, including studies evaluating novel therapeutic approaches for Crohn's Disease and Ulcerative Colitis.

  • Dazodalibep safety trials
  • Combination therapy assessments
  • Advanced treatment protocols

Multiple studies investigating long-term effectiveness and patient outcomes in chronic inflammatory conditions.

02 Cardiovascular Research

Comprehensive studies addressing cardiovascular disease and related conditions, including research on lipoprotein management and cardiac inflammation treatments.

  • Lipid-lowering therapies
  • Acute myocarditis treatment
  • Pulmonary embolism management

Focus on preventive measures and innovative therapeutic approaches for various cardiac conditions.

03 Oncology Studies

Advanced research in cancer treatment, including studies on breast cancer, melanoma, and various blood cancers.

  • Endocrine therapy optimization
  • Immunotherapy combinations
  • Leukemia treatment protocols

Emphasis on personalized treatment approaches and improved patient outcomes.

Back to SloveniaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.